P-BCMA-101 Clinical Data Presented at CAR-TCR Summit

Poseida Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma Poseida Therapeutics Inc. – a clinical-stage biotechnology company translating best-in-class gene engineering technologies into lifesaving cell therapies – announced data results from the first eleven patients treated in its ongoing Phase 1 study of its…


Myeloma UK is helping to Make Blood Cancer Visible this September

Myeloma UK is helping to Make Blood Cancer Visible in September. The campaign, in partnership with Janssen Oncology and eight patient organisations, marks Blood Cancer Awareness Month. It will feature a public art installation, which will help visitors to understand the experiences of people affected by blood cancer.   The installation is made up of…


Darzalex gains EU approval for new frontline combination treatment

Janssen has announced EU approval of Darzalex (daratumumab) for use alongside Takeda’s Velcade (bortezomib), melphalan and prednisone (VMP) for newly diagnosed myeloma patients who are ineligible for high-dose chemotherapy and autologous stem cell transplant (ASCT). The approval is based on results of the ALCYONE clinical trial which showed that adding Darzalex to VMP reduces the risk of…